{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":33,"description":"Minocycline 100 mg (capsule) two times a day to begin with start of maintenance therapy (3 months +/- 2 days)","id":"EG000","otherNumAffected":3,"otherNumAtRisk":33,"seriousNumAffected":0,"seriousNumAtRisk":33,"title":"Minocycline"},{"deathsNumAffected":0,"deathsNumAtRisk":36,"description":"Placebo 100 mg (capsule) two times a day to begin with start of maintenance therapy (3 months +/- 2 days)","id":"EG001","otherNumAffected":4,"otherNumAtRisk":36,"seriousNumAffected":0,"seriousNumAtRisk":36,"title":"Placebo"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33},{"groupId":"EG001","numAffected":1,"numAtRisk":36}],"term":"Anxiety"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33},{"groupId":"EG001","numAffected":0,"numAtRisk":36}],"term":"Back pain"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33},{"groupId":"EG001","numAffected":3,"numAtRisk":36}],"term":"Blurred Vision"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33},{"groupId":"EG001","numAffected":4,"numAtRisk":36}],"term":"Constipation"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33},{"groupId":"EG001","numAffected":1,"numAtRisk":36}],"term":"Cough"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33},{"groupId":"EG001","numAffected":1,"numAtRisk":36}],"term":"Cytopenia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33},{"groupId":"EG001","numAffected":2,"numAtRisk":36}],"term":"Diarrhea"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":33},{"groupId":"EG001","numAffected":2,"numAtRisk":36}],"term":"Dizziness"}],"timeFrame":"From the start of the study medication, up to 30 days after last dose administered, up to a total of 4 months"}